Intended for healthcare professionals

Rapid response to:

Editorials

Dexamethasone in the management of covid -19

BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m2648 (Published 03 July 2020) Cite this as: BMJ 2020;370:m2648

Read our latest coverage of the coronavirus pandemic

Rapid Response:

Immune modulation as treatment for severe COVID-19: a light at the end of the tunnel, Re: Dexamethasone in the management of covid -19

Dear Editor

Johnson and Vinetz recently editorialized on the results of the preprint RECOVERY trial [1], which showed a clear benefit of dexamethasone (6 mg daily) on all-cause mortality in patients with severe and critical COVID-19. [2] They highlighted that some gaps still exist regarding the usefulness of dexamethasone in the treatment of patients with this condition, and emphasized that “it is not clear whether corticosteroids are the best option for all patients in the second phase of the illness…” [2].

Johson and Vinetz did not mention another important study dealing with immune modulation of patients with COVID-19, which showed a clear benefit in the clinical deterioration status (the primary end-point) and in all-cause mortality (a prespecified secondary endpoint) of patients with this condition: the GRECCO study. In that study, clinical deterioration was based on a 7-level ordinal scale ranging from level 1 (ambulatory, normal activities), to level 4 (hospitalized, requiring supplemental oxygen) and to level 7 (death). Clinical deterioration was defined as a 2-level increase on this ordinal scale. [3]

In GRECCO, Deftereos et al. randomized 105 patients with severe COVID-19 to be treated with either colchicine (n=55) or usual care (n=50); all patients had positive polymerase chain reaction–reverse transcriptase testing. The average time from hospitalization to randomization was 3 days. About 65% of patients had severe (level 4), and 35% moderate COVID-19 (level 3). No patients with critical COVID-19 were enrolled. Background therapy consisted of anticoagulation in 50% of patients, and hydroxychloroquine in 100%. Deterioration in clinical status occurred in 14% of control and in 2% of colchicine group (p=0.02). Furthermore, cumulative 10-day survival was 97% in colchicine x 83% in control group (p=0.03).

Despite the limitation of the sample size, which was much lower in GRECCO than in RECOVERY trial (6425 patients enrolled; 2104 to dexamethasone group x 4321 to usual care), [2,3] the GRECCO trial results suggest that colchicine might be an option when dexamethasone is contraindicated for patients with severe COVID-19, as 61% of patients in RECOVERY had this condition. Furthermore, they also suggest that colchicine might be of benefit to patients with moderate COVID-19. Therefore, we suggest that doctors in the frontline take into account both evidence-based medicine possibilities for treating COVID-19.

No competing interest

1. Horby P, Lim WS, Emberson J, et al. Effect of dexamethasone in hospitalized patients with Covid-19: preliminary report. MedRxiv 2020.06.2220.06137273 (Preprint). https://doi.org10.1101/2020.06.22.20137273
2. Jonhson RM, Vinetz JM. Dexamethasone in the management of COVID-19. BMJ 370: doi 10.1136/bmg.m2648.
3. Deftereos SG, Giannopoulos G, Vrachatis DA, et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019. JAMA Network Open. 2020;3(6):e2013136. doi:10.1001/jamanetworkopen.2020.13136

Reinaldo B. Bestetti, MD, PhD* ORCID: 0000-0002-4488-9601/
Rosemary Furlan-Daniel, MD, PhD ORCID: 0000-0002-7375-8205

Competing interests: No competing interests

26 July 2020
Reinaldo B Bestetti
doctor, teacher
Rosemary Furlan Daniel
University of Ribeirão Preto- Brazil- Course of Medicine
Av, Costabile Romano, 2200. Zip Code: 14096-900 Ribeirão Preto, Brazil.